Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities.
Department of Dermatology, Brigham and Women's Hospital, Boston, MA, U.S.A.|Centre for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 375 Longwood Avenue, Boston, MA, 02115, U.S.A.
A
A
Alloo
Harvard Medical School, Boston, MA, U.S.A.
J
J
Sheu
Centre for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 375 Longwood Avenue, Boston, MA, 02115, U.S.A.|Harvard Medical School, Boston, MA, U.S.A.
J E
JE
Butrynski
Harvard Medical School, Boston, MA, U.S.A.|Centre for Hematological Oncology, Dana Farber Cancer Institute, 375 Longwood Avenue, Boston, MA, 02115, U.S.A.
D J
DJ
DeAngelo
Centre for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 375 Longwood Avenue, Boston, MA, 02115, U.S.A.|Harvard Medical School, Boston, MA, U.S.A.
S
S
George
Harvard Medical School, Boston, MA, U.S.A.|Department of Pathology, Brigham and Women's Hospital, Boston, MA, U.S.A.
G F
GF
Murphy
Department of Dermatology, Brigham and Women's Hospital, Boston, MA, U.S.A.|Harvard Medical School, Boston, MA, U.S.A.|Centre for Cutaneous Oncology, Dana Farber Cancer Institute, 375 Longwood Avenue, Boston, MA, 02115, U.S.A.
N R
NR
LeBoeuf
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005499:Folliculitis / Q000139:chemically induced; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced; D007093:Imidazoles / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010915:Pityriasis / Q000139:chemically induced; D011724:Pyridazines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib